Price Alert

Turning Point Therapeutic... (TPTX)

NASDAQ: TPTX · Real-Time Price · USD

75.49

0.09 (0.12%)

At close: Aug 15, 2022, 10:00 PM

Turning Point Therapeutics Statistics

Share Statistics

Turning Point Therapeutics has 0 shares outstanding. The number of shares has increased by 1.08% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	1.08%
Shares Change (QoQ)	0.42%
Owned by Institutions (%)	n/a
Shares Floating	48.2M
Failed to Deliver (FTD) Shares	n/a
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 1.77M, so 0% of the outstanding shares have been sold short.

Short Interest	1.77M
Short % of Shares Out	n/a
Short % of Float	4.15%
Short Ratio (days to cover)	1.88

Valuation Ratios

The PE ratio is -8.24 and the forward PE ratio is null. Turning Point Therapeutics's PEG ratio is -0.16.

PE Ratio	-8.24
Forward PE	n/a
PS Ratio	63.2
Forward PS	n/a
PB Ratio	2.04
P/FCF Ratio	-12.46
PEG Ratio	-0.16

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Turning Point Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 21.08, with a Debt / Equity ratio of 0.01.

Current Ratio	21.08
Quick Ratio	21.08
Debt / Equity	0.01
Debt / EBITDA	-0.02
Debt / FCF	-0.04
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$115.46K
Profits Per Employee	$-885.96K
Employee Count	267
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	1.45M
Effective Tax Rate	-0.61%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is -0.19, so Turning Point Therapeutics's price volatility has been lower than the market average.

Beta	-0.19
52-Week Price Change	n/a
50-Day Moving Average	74.99
200-Day Moving Average	n/a
Relative Strength Index (RSI)	74.83
Average Volume (20 Days)	n/a

Income Statement

In the last 12 months, Turning Point Therapeutics had revenue of 30.83M and earned -236.55M in profits. Earnings per share was -5.79.

Revenue	30.83M
Gross Profit	30.83M
Operating Income	-236.55M
Net Income	-236.55M
EBITDA	-232.58M
EBIT	-236.55M
Earnings Per Share (EPS)	-5.79

Full Income Statement

Balance Sheet

The company has 427.88M in cash and 5.58M in debt, giving a net cash position of 422.3M.

Cash & Cash Equivalents	427.88M
Total Debt	5.58M
Net Cash	422.3M
Retained Earnings	-516.73M
Total Assets	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -153.88M and capital expenditures -2.43M, giving a free cash flow of -156.31M.

Operating Cash Flow	-153.88M
Capital Expenditures	-2.43M
Free Cash Flow	-156.31M
FCF Per Share	-3.83

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -767.3% and -767.3%.

Gross Margin	100%
Operating Margin	-767.3%
Pretax Margin	-767.3%
Profit Margin	-767.3%
EBITDA Margin	-754.43%
EBIT Margin	-767.3%
FCF Margin	-507.03%

Dividends & Yields

TPTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for TPTX.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a